Ex vivo ultrasonic samples of human brain tumors in the molecular era

Alastair J. Kirby¹,†, José P. Lavrador²,†, Istvan Bodi¹,³, Francesco Vergani², Ranjeev Bhangoo², Keyoumars Ashkan¹,², Gerald T. Finnerty¹,⁴,*

¹Department of Basic and Clinical Neuroscience, King’s College London, De Crespigny Park, London SE5 8AF, UK; ²Department of Neurosurgery, King’s College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK; ³Department of Clinical Neuropathology, King’s College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK; ⁴Department of Neurology, King’s College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK.

†These authors contributed equally

*Corresponding Author: G.T.F. (gerald.finnerty@kcl.ac.uk), Tel: +44 20 3299 8352

Running Title: Ex vivo ultrasonic samples of brain tumors

Funding: Medical Research Council DTP PhD studentship to AJK (MR/N013700/1), Psychiatry Research Trust and Inman Charity.

Conflict of Interest: AJK is CEO of Vivisco Limited. GTF and AK are shareholders and sit on the Advisory Board. Vivisco did not contribute materials or funds to this project.

Authorship: AJK, JPL & GTF designed the study. AJK, JPL, FV, RB, KA collected samples and intraoperative images. AJK did the experimental work. AJK and GTF analysed the data. IB (Consultant Neuropathologist) made the neuropathological diagnoses. AJK, JPL & GTF wrote the manuscript with input from FV, RB, IB and KA.

This article has been accepted for publication in Neuro-Oncology Advances Published by Oxford University Press.
Abstract

**Background.** Gliomas are composed of multiple clones of tumor cells. This intratumor heterogeneity contributes to the ability of gliomas to resist treatment. It is vital that gliomas are fully characterized at a molecular level when a diagnosis is made to maximize treatment effectiveness.

**Methods.** We collected ultrasonic tissue fragments during glioma surgery. Large tissue fragments were separated in the operating theatre and bathed continuously in oxygenated artificial cerebrospinal fluid to keep them alive. The *ex vivo* tissue fragments were transferred to a laboratory and incubated in 5-aminolevulinic acid (5-ALA). 5-ALA is metabolised to Protoporphyrin IX (PpIX), which accumulates in glioma cells and makes them fluorescent. The molecular and neuropathological features of the PpIX fluorescent ultrasonic tissue fragments were studied.

**Results.** We show that PpIX fluorescence can rapidly identify tissue fragments infiltrated by glioma in the laboratory. Ultrasonic tissue fragments from the tumor core provided molecular and neuropathological information about the glioma that was comparable to the surgical biopsy. We characterized the heterogeneity within individual gliomas by studying ultrasonic tissue fragments from different parts of the tumor. We found that gliomas exhibit a power relationship between cellular proliferation and tumor infiltration. Tissue fragments that deviate from this relationship may contain foci of more malignant glioma. The methylation status of the O\(^6\)-methylguanine DNA methyltransferase (MGMT) gene promoter varied within each glioma.

**Conclusion.** *Ex vivo* ultrasonic tissue fragments can be rapidly screened for glioma infiltration. They offer a viable platform to characterize heterogeneity within individual gliomas, thereby enhancing their diagnosis and treatment.
Keywords: Glioma, tumor heterogeneity, molecular marker, 5-aminolevulinic acid, Protoporphyrin IX,

Key points

- 5-ALA induced fluorescence detects glioma infiltration in *ex vivo* brain tissue
- Ultrasonic tissue fragments from gliomas provide diagnostic molecular information
- 5-ALA screened ultrasonic tissue fragments can reveal intratumoral heterogeneity

Importance of the study

Gliomas are comprised of multiple clones of tumor cells. This intratumor heterogeneity is a key factor in the ability of gliomas to resist treatment. It is vital that gliomas have a full molecular characterization at diagnosis to maximize treatment efficacy. We developed a rapid fluorescence-based screening protocol to identify glioma infiltration in *ex vivo* brain tissue fragments collected by ultrasonic aspirators. We show that brain tissue fragments provide molecular information that is relevant to diagnosis and treatment. We propose that *ex vivo* ultrasonic tissue fragments are a valuable resource that can be used to assess intratumoral heterogeneity.
Gliomas were originally classified according to their histopathological features. Recently, however, greater emphasis has been placed on the molecular profile of gliomas for diagnosis and prognosis.\textsuperscript{1} In parallel, precision medicine treatments of gliomas are being based on the molecular profiles of the glioma cells.

Research studies have employed molecular profiling to show that gliomas do not have a uniform cellular composition, but rather are composed of multiple cell types at different stages of differentiation.\textsuperscript{2-5} Therefore, a neuropathological diagnosis of gliomas is most accurate when multiple sites within the tumor are sampled.\textsuperscript{6} This presents a problem when the tumor is near an eloquent area or is difficult to access surgically.

Ultrasonic aspirators generate small fragments of tissue that are aspirated as they are produced.\textsuperscript{7} These devices can remove tumor tissue while leaving neighbouring, healthy brain parenchyma and blood vessels intact. This feature combined with their ease of use meant that they were rapidly adopted by neurosurgeons for microsurgical dissection of brain tumors.\textsuperscript{8}

It was quickly realised that the tissue fragments generated by ultrasonic aspirators may have diagnostic value. Concerns were raised that the small samples produced by ultrasonic aspirators may not show key histopathological features, such as necrosis, and that the process of fragmenting the tissue may cause artefacts.\textsuperscript{9} However, other studies of brain tumor samples produced by ultrasonic aspirators indicate that they recapitulate many of the histopathological\textsuperscript{10} and immunocytochemical\textsuperscript{11} features found in the larger samples collected with brain tumor biopsy forceps. Moreover, ultrasonic aspirators make it very easy to take samples from multiple parts of the tumor. Despite this, ultrasonic sampling of brain tumors is not in widespread, clinical use.
The ability to screen ultrasonic tissue fragments for tumor infiltration would greatly increase their clinical value. Fluorescence imaging has been used to detect tumor per-operatively.\textsuperscript{12-16}

We used the same approach to identify ultrasonic tissue fragments infiltrated with glioma. These ultrasonic tissue fragments were stored under acute conditions used by neuroscientists to keep brain tissue alive.\textsuperscript{17,18} We found that the ultrasonic samples recapitulated the molecular features of the biopsy samples that are collected routinely. Furthermore, ultrasonic samples taken from different parts of the glioma showed heterogeneity in the methylation status of the MGMT gene promoter and cellular proliferation indices. Our findings suggest that ultrasonic samples can play a valuable role as an adjunct to brain tumor biopsy in both diagnosis and planning treatment.

**Materials and Methods**

*Ethics approval and consent to participate*

The UK Human Research Authority (https://www.hra.nhs.uk/) approved the collection of brain samples following a favourable opinion from the South West Research Ethics Committee (REC approval code: 18/SW/0022). Brain samples were donated by participants with a suspected diffuse astrocytic or oligodendroglial tumor\textsuperscript{1} who had not had brain surgery previously or received chemotherapy or radiotherapy. All participants gave informed consent prior to their surgery. The consent included permission to use and present their data.

*Intraoperative 5-ALA-induced fluorescence*

All participants were given 20 mg/kg of 5-ALA two hours prior to their craniotomy for a fluorescence-guided tumor resection at King’s College Hospital, London between January 2019 and September 2019. The neurosurgeon recorded whether (s)he could see 5-ALA-
induced fluorescence with the operating microscope (Zeiss OPMI Pentero 900 or Zeiss KINEVO 900 operating microscope) during the surgery.

**Intraoperative sample collection**

Ultrasonic samples were collected during surgery with a Sonopet ultrasonic aspirator (Stryker Corp, MI, USA) with an angled handpiece and straight, soft tissue tip (outer diameter 1.92 mm, inner diameter 1.50 mm) oscillating at 25 kHz. Tissue fragments were collected with the following console settings: aspiration 5 - 10%, power 5 - 10% and irrigation 5 - 10%. The anatomical location of the tissue samples was documented with either the intraoperative surgical navigation system (Stealth S7 or S8, Medtronic, Minneapolis, USA) or intraoperative ultrasound (ESAOTE), combined with intraoperative images (Zeiss OPMI Pentero 900 or Zeiss KINEVO 900 operating microscope) of the exposed brain (Figure 1A, B). The tissue fragments were collected in a specimen trap (Pennine, MST-3070) connected to the Sonopet aspiration system (Figure 1C). The tumor biopsy was given preference when tissue was collected as the tumor biopsy was used for diagnosis and the ultrasonic samples were not.

The operating surgeon co-ordinated collection of the ultrasonic samples to ensure tumor samples from known locations were sampled. When the specimen trap was filled, the contents were passed through a nylon mesh to separate larger tissue fragments from the smaller fragments. The larger fragments were rinsed with cerebrospinal fluid (CSF) that had been modified to prevent neural firing and excitotoxicity. The transportation CSF comprised (in mM): 108 choline-Cl, 3 KCl, 26 NaHCO$_3$, 1.25 NaHPO$_4$, 25 D-glucose, 3 Na pyruvate, 2 CaCl$_2$, 1 MgCl$_2$ and 1 Heparin, which had been cooled to 4 °C and bubbled with 95% Oxygen / 5% CO$_2$. The large tissue fragments were then transferred to a *ex vivo* tissue
transportation system, which keeps the tissue fragments cool while bathing them in transportation CSF.\textsuperscript{20}

After arriving in the laboratory, the ultrasonic samples were transferred to an incubation chamber. The artificial CSF used for the incubation chamber was changed to (mM): 120 NaCl, 3 KCl, 23 NaHCO$_3$, 1.25 NaHPO$_4$, 10 D-glucose, 2 CaCl$_2$, and 1 MgCl$_2$ bubbled with 95% Oxygen / 5% CO$_2$. The artificial CSF was gradually warmed to 37 °C. The larger fragments were imaged and then processed for a neuropathological and molecular diagnosis (Figure 1D – F).

Ex vivo imaging

PpIX photobleaches quickly.\textsuperscript{21} This makes it harder to see low levels of PpIX fluorescence with an operating microscope. Therefore, we stored ex vivo ultrasonic tissue fragments in a low volume incubation chamber (Scientific Systems Design, Ontario, Canada) and bathed the tissue fragments in 1 mM 5-ALA (Sigma: 5451-09-2) for thirty minutes prior to experiments, which was continued during experiments.\textsuperscript{21}

The ultrasonic samples were imaged on an interface recording chamber\textsuperscript{22} (Scientific Systems Design, Ontario, Canada), which was mounted on an Olympus BX51WI epifluorescence microscope. A custom filter set (excitation 402/15 nm, emission 654/75 nm; Chroma Technology Corp, VT, USA) was fitted to the filter cube turret of the BX51WI microscope to detect PpIX fluorescence. The laboratory fluorescence images and brightfield images were acquired on a Spot RT sCMOS cooled 5MP camera (RT39M5, Spot Imaging, USA) controlled by Spot Advanced imaging software (Spot Imaging, USA).
The fluorescence signal was quantified in FIJI (https://imagej.net/Fiji). The mean pixel intensity of the background (no tissue) was subtracted from pixel intensity in the tissue fragment region of interest. The pixel intensities in the region of interest were summed and divided by the area of the region of interest to give a total fluorescence signal x 10^7 per mm^2, which is expressed in relative fluorescence units (RFU).

**Neuropathological processing**

*Ex vivo* ultrasonic samples from the edge and core of high-grade gliomas were imaged in the laboratory in five participants. Both the core and edge samples were then processed histologically for tumor markers. The tissue fragments were fixed in 10% formalin and embedded in paraffin blocks. 4 - 5 µm sections were cut for immunohistochemistry. Immunohistochemistry, diagnostic genetic testing and neuropathological assessment of brain tumors were performed by the Department of Clinical Neuropathology, King’s College Hospital, which is accredited by the United Kingdom Accreditation System and works in accordance with ISO standards 15189 for medical laboratories.

Neuropathology slides were imaged on an Olympus Slide scanner VS120. The images were analysed with FIJI software (https://imagej.net/Fiji). A circularity and size filter were applied to the identified objects in the image. The filter parameters were adjusted to select rounded tumor cells and to discard nestin-positive endothelial cells, which were more elongated. The methylation status of the MGMT gene promoter at four CpG sites was determined by pyrosequencing using the *therascreen* MGMT pyro kit (Qiagen, Hilden, Germany).

**Statistical analysis**
Graph Pad Prism 8 was used for statistical analysis and graphing. Normally-distributed data were described by their mean ± standard error. The linear regression function was used to fit lines to data. Statistical tests were two-tailed and had a threshold for type 1 statistical error of $\alpha < 0.05$. Means were compared with t-tests or a repeated measures ANOVA (MGMT gene promoter methylation) if the data fulfilled the assumptions for parametric tests. A Mann-Whitney U-test was used when parametric tests were not appropriate. The power relationship between cell proliferation, measured by the density of Ki-67 positive nuclei, and tumor infiltration was assumed to be:

$$\text{Ki-67 positive nuclei} = k(\text{tumor infiltration})^n$$

where $k$ is a constant and $n$ is the power value. The data were plotted in the log – log format (Figure 4F) so that the slope of the line estimates the power, $n$, and the intercept with the x-axis when log Ki-67 positive nuclei equals zero (dashed line Figure 4F) gives a measure of the number of tumor cells that are present when one cell is proliferating.

**Results**

The presence of glioma cells in the screened ultrasonic tissue fragments was confirmed with histochemical stains and immunocytochemical stains against brain tumor markers (Figure 1).

*Ultrasonic tissue fragments exhibit histopathological features of gliomas*

The World Health Organization (WHO) grading of brain tumors is based on the histopathological and the molecular features of the tumors.\(^1\) We first investigated the histopathological features that were exhibited by ultrasonic tissue fragments from WHO grade III – IV gliomas. A consultant neuropathologist (IB) examined the ultrasonic tissue fragments for histopathological features of cell division (mitotic figures), vascular proliferation, necrosis and presence of pleomorphic cells or gemistocytes and compared the
findings with the results from the tumor biopsy. The probability of the ultrasonic samples exhibiting a histopathological feature found in the tumor biopsy was 0.33 – 1.0 (n = 7 gliomas; Figure 2A, Table 1).

We found that a tumor diagnosis could be made from the histopathological features exhibited by the ultrasonic samples in 6/7 cases. In one case, there were too few glioma cells in the ultrasonic samples to reach a diagnosis. We concluded that large ultrasonic tissue fragments could give histopathological information about the tumor if the tissue fragments were taken from the body of the tumor and avoided large areas of necrosis as reported previously.\textsuperscript{9,10,24}

\textit{Molecular markers in ultrasonic tissue fragments}

Molecular markers have become increasingly important to the diagnosis and management of gliomas.\textsuperscript{1} We asked whether ultrasonic tissue fragments provided quantifiable information about molecular markers. We first investigated markers of cellular proliferation in the ultrasonic samples by studying expression of the Ki-67 protein in the nucleus (Figure 1E). We found that percentage of cells expressing Ki-67 in the ultrasonic samples from the tumor core was within 7.9 ± 4.0 % (n = 6 gliomas) of the Ki-67 expression in the tumor biopsy (Figure 2B, C).

We next studied the methylation status of the promoter region of the MGMT gene. The MGMT protein is important therapeutically because it removes the alkyl groups on guanine bases that are added by the chemotherapy drug, temozolomide. Methylation of the CpG dinucleotides in the promoter of the MGMT gene reduces expression of the MGMT protein, which enhances the cytotoxicity of temozolomide. The average percentage methylation of the MGMT gene promoter in the ultrasonic tissue fragments taken from the core of the tumor
were comparable to the values for the diagnostic biopsy (mean percentage difference 1.5 ± 0.6 %, n = 5 gliomas; Figure 2B, C). We concluded that ultrasonic samples can provide quantifiable information about molecular markers relevant to the diagnosis and management of gliomas.

Fluorescence imaging to screen ex vivo ultrasonic tissue fragments for glioma infiltration

PpIX fluorescence was seen intraoperatively with the operating microscope in 4/7 participants (0/1 WHO grade II, 1/3 WHO grade III, 3/3 WHO grade IV; Table 2). PpIX fluorescence was seen in the ultrasonic samples from 6/7 participants. In one participant with an anaplastic oligodendroglioma (case G, Table 2), no fluorescence was seen intraoperatively or during screening of ultrasonic samples. In this case, very few glioma cells were present in the ultrasonic samples. We concluded that screening of ultrasonic tissue fragments with PpIX can detect infiltration by high-grade glioma cells at lower levels than seen during surgery.

We next explored whether ultrasonic samples could contribute to the evaluation of heterogeneity within a glioma. Histopathological screening for tumor infiltration in each fragment before molecular analysis would not be sustainable due to the large number of fragments collected during the surgery. Therefore, we developed a method to screen ex vivo ultrasonic tissue fragments for glioma infiltration using fluorescence imaging (Materials and Methods).

We took advantage of the 5-ALA induced fluorescence that is used by neurosurgeons to image WHO grade III - IV gliomas during surgery.5-ALA is metabolized in cells to Protoporphyrin IX (PpIX), which accumulates in glioma cells and causes them to be fluorescent (Figure 3A, B). For tumors exhibiting PpIX fluorescence during surgery, the core
was defined as a brain region where a fluorescence signal was visible with the operating microscope whereas the tumor edge exhibited no fluorescence (Figure 3B, C; Materials and Methods).

PpIX fluorescent cells could be seen in ex vivo ultrasonic tissue fragments taken from the tumor edge. The relative PpIX fluorescence emitted by ex vivo ultrasonic tissue fragments from the tumor core was higher than from the tumor edge (mean relative PpIX fluorescence: core = 8.0 ± 1.3 RFU, n = 4; edge = 2.5 ± 0.9 RFU, n = 5; p = 0.010, t-test; Figure 3D – F).

We calculated a second, separate immunocytochemical measure of tumor infiltration by quantifying high-grade glioma cells that were positive for either nestin or for IDH1 (R132H) mutant protein at the core and tumor edge (Figure 4A, B). Ultrasonic tissue fragments from the core of the tumor had a higher density of glioma cells than the edge (core = 2512 cells.mm⁻², edge = 200 cells.mm⁻², n = 4 gliomas, p = 0.015 paired t-test; Figure 4B, data logged for presentation).

We then compared the relationship between relative PpIX fluorescence imaging and tumor infiltration measured immunocytochemically. There was not a tight relationship between the relative PpIX fluorescence signal and the extent of tumor infiltration (R² = 0.28, p = 0.18, n = 8; Figure 4C). We explored this further by studying the spatial distribution of PpIX fluorescent cells. The tumor core was densely labelled with PpIX fluorescent cells (Figure 4D). At the tumor edge, the PpIX fluorescent cells were not evenly distributed, but, were frequently found clustered together (Figure 4D).
We concluded that *ex vivo* ultrasonic tissue fragments could be screened for tumor infiltration with fluorescence imaging. The screening can be done rapidly because the tissue fragments do not need resectioning. The tendency for PpIX fluorescent cells to form small cell clusters made it easier to detect low levels of tumor infiltration at the tumor edge.

*Ex vivo ultrasonic samples to assess tumor heterogeneity*

The *ex vivo* ultrasonic tissue fragments exhibiting PpIX fluorescence were used to study heterogeneity within high-grade gliomas.

We first asked whether *ex vivo* ultrasonic tissue fragments gave information on variability in cell proliferation in different parts of the high-grade gliomas. We stained *ex vivo* ultrasonic samples from different parts of a tumor for Ki-67 to measure cell proliferation (Figure 4E) and immunocytochemical tumor markers to quantify tumor infiltration. We found that cell proliferation, measured by the density of Ki-67 positive nuclei, had a power relationship with tumor infiltration for each glioma (Figure 4F; Materials and Methods). The power values for high-grade gliomas (WHO grade III – IV) ranged from 0.7 – 1.4 (Figure 4F). The lines from the more aggressive glioblastomas were to the left of the anaplastic astrocytomas (Figure 4F).

Next, we focused on the methylation status of the MGMT gene promoter. The mean value for the methylation status of *ex vivo* ultrasonic tissue fragments from the core was similar to the values for the surgical biopsy (surgical biopsy = 15.3%, *ex vivo* ultrasonic samples, core = 15.5%, edge = 3.9%; repeated measures ANOVA, p = 0.069) (Figure 4G). However, we found differences of up to 3.6%, which may be important in borderline cases (Figure 4G).
We concluded that *ex vivo* ultrasonic tissue fragments can capture variability in molecular markers, such as MGMT gene promoter methylation in the tumor core. Hence, ultrasonic tissue fragments can add to the surgical biopsy by giving information about tumor heterogeneity.

**Discussion**

We investigated whether *ex vivo* ultrasonic samples of brain tissue can facilitate the diagnosis and treatment of gliomas. We show that large *ex vivo* ultrasonic tissue fragments can be screened rapidly with fluorescence imaging to detect tissue fragments infiltrated with tumor. These tumor-infiltrated tissue fragments give detailed information about the molecular features of the tumor. This molecular information can be obtained either with immunocytochemical stains or through genetic sequencing. Importantly, ultrasonic tissue fragments give quantifiable data. Therefore, they can be used to characterize heterogeneity within a glioma. Consequently, ultrasonic samples can play a valuable role as an adjunct to brain tumor biopsy in both diagnosis and planning treatment.

Molecular profiling of ultrasonic tissue fragments would be easy to implement if there was a simple way to screen the tissue fragments for tumor infiltration. Fluorescence screening is the option we pursued. Ideally, the fluorescent label would only be expressed in glioma cells. One strategy is to use fluorophores that are actively concentrated within glioma cells. Therefore, we stored ultrasonic tissue fragments under *ex vivo* conditions to keep the brain tissue alive.\(^{17,18}\) We found that increased levels of PpIX in glioma cells can be used to detect tumor infiltration in *ex vivo* ultrasonic samples.
Tumor recurrence is a major problem in the management of brain tumors. A key issue is intratumor heterogeneity. The heterogeneity can be captured by collecting ultrasonic samples from different parts of the tumor. We found that individual gliomas manifested a power relationship between cellular proliferation, measured by Ki-67 expression, and tumor infiltration (Figure 4F). Higher-grade tumors showed greater cellular proliferation indices. Points above the line for a tumor indicate foci of higher than expected proliferation within the tumor and may serve as an early indicator of more malignant tumor behaviour. The brain location of the tissue fragments can be recorded with the surgical neuronavigation system. Therefore, the collection site of tissue fragments with unexpectedly high proliferation indices can be identified. This information may be useful when planning treatment, such as radiotherapy.

The methylation status of the MGMT gene promoter is used to predict the response of gliomas to alkylating chemotherapy agents. Heterogeneity in the methylation status of tumor cells within individual gliomas has been described. The extent of heterogeneity in MGMT gene promoter methylation within gliomas requires further evaluation. It may be affected by several factors including the number of glioma cell clones in the tumor, tumor microenvironment and developmental status of individual glioma cells. We found that screened ultrasonic tissue fragments capture the intratumoral heterogeneity. Notably, the MGMT gene promoter methylation in one of four participants was higher than reported from the surgical biopsy (Figure 4G). Hence, information from the ultrasonic tissue fragments gives a broader overview of methylation status within the tumor and may affect treatment decisions in cases of borderline methylation status.
Research studies have used the fluid from ultrasonic aspirators as a source of glioma cells for culturing and xenotransplantation into mice.\textsuperscript{25,29,30} Commonly, larger tissue fragments have been dissociated prior to culturing.\textsuperscript{25} Contamination of these cultures with healthy cells has been a concern in therapy studies.\textsuperscript{30} Fluorescence screening reduces this problem. Going forwards, screened \textit{ex vivo} fragments could be used directly in research involving 3D glioma models rather than being dissociated first.

The diagnosis and management of brain tumors is increasingly determined by the molecular profile of the tumor. This trend is accelerating. Tissue fragments from ultrasonic aspirators provide valuable molecular information that aids diagnosis. Treatment of brain tumors will increasingly be guided by actionable mutations in the tumor. Live ultrasonic tissue fragments are an underused source of tumor tissue that have great potential to improve how patients are diagnosed and treated.

\textbf{Acknowledgements}

We thank Natalie Long for assistance with recruitment.

\textbf{References}

1. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. \textit{Acta Neuropathol.} 2016; 131(6):803-820.

2. Patel AP, Tirosh I, Trombetta JJ, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. \textit{Science.} 2014; 344(6190):1396-1401.

3. Puchalski RB, Shah N, Miller J, et al. An anatomic transcriptional atlas of human glioblastoma. \textit{Science.} 2018; 360(6389):660-663.
4. Neftel C, Laffy J, Filbin MG, et al. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. *Cell*. 2019; 178(4):835-849 e821.

5. Sottoriva A, Spiteri I, Piccirillo SG, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. *Proc Natl Acad Sci U S A*. 2013; 110(10):4009-4014.

6. Zadeh G, Salehi F, An S, et al. Diagnostic implications of histological analysis of neurosurgical aspirate in addition to routine resections. *Neuropathology*. 2012; 32(1):44-50.

7. Bond LJ, Cimino WW. Physics of ultrasonic surgery using tissue fragmentation. *Ultrasonics*. 1996; 34(2-5):579-585.

8. Flamm ES, Ransohoff J, Wuchinich D, Broadwin A. Preliminary experience with ultrasonic aspiration in neurosurgery. *Neurosurgery*. 1978; 2(3):240-245.

9. Blackie RA, Gordon A. Histological appearances of intracranial biopsies obtained using the Cavitron ultrasonic surgical aspirator. *J Clin Pathol*. 1984; 37(10):1101-1104.

10. Richmond IL, Hawksley CA. Evaluation of the histopathology of brain tumor tissue obtained by ultrasonic aspiration. *Neurosurgery*. 1983; 13(4):415-419.

11. Finley JL, Silverman JF, Dickens MA. Immunocytochemical evaluation of central nervous system tumors obtained by the Cavitron ultrasonic surgical aspirator. *Diagn Cytopathol*. 1990; 6(5):308-312.

12. Martirosyan NL, Georges J, Eschbacher JM, et al. Confocal scanning microscopy provides rapid, detailed intraoperative histological assessment of brain neoplasms: Experience with 106 cases. *Clin Neurol Neurosurg*. 2018; 169:21-28.
13. Krishnamurthy S, Cortes A, Lopez M, et al. Ex Vivo Confocal Fluorescence Microscopy for Rapid Evaluation of Tissues in Surgical Pathology Practice. *Arch Pathol Lab Med.* 2018; 142(3):396-401.

14. Piccirillo SG, Dietz S, Madhu B, et al. Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin. *Br J Cancer.* 2012; 107(3):462-468.

15. Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. *Lancet Oncol.* 2006; 7(5):392-401.

16. Cho SS, Salinas R, Lee JYK. Indocyanine-Green for Fluorescence-Guided Surgery of Brain Tumors: Evidence, Techniques, and Practical Experience. *Front Surg.* 2019; 6:11.

17. Eugene E, Cluzeaud F, Cifuentes-Diaz C, et al. An organotypic brain slice preparation from adult patients with temporal lobe epilepsy. *J Neurosci Methods.* 2014; 235:234-244.

18. Ting JT, Kalmbach B, Chong P, et al. A robust ex vivo experimental platform for molecular-genetic dissection of adult human neocortical cell types and circuits. *Sci Rep.* 2018; 8(1):8407.

19. Albieri G, Barnes SJ, de Celis Alonso B, et al. Rapid bidirectional reorganization of cortical microcircuits. *Cereb Cortex.* 2015; 25:3025-3035.

20. Kohling R, Lucke A, Straub H, Speckmann EJ. A portable chamber for long-distance transport of surviving human brain slice preparations. *J Neurosci Methods.* 1996; 67(2):233-236.

21. Moan J, Streckyte G, Bagdonas S, Bech O, Berg K. Photobleaching of protoporphyrin IX in cells incubated with 5-aminolevulinic acid. *Int J Cancer.* 1997; 70(1):90-97.
22. Hill MR, Greenfield SA. The membrane chamber: a new type of in vitro recording chamber. *J Neurosci Methods*. 2011; 195(1):15-23.

23. Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: an open-source platform for biological-image analysis. *Nat Methods*. 2012; 9(7):676-682.

24. Malhotra V, Malik R, Gondal R, Beohar PC, Parkash B. Evaluation of histological appearance of tissues removed by cavitron ultrasonic surgical aspirator (CUSA). *Acta Neurochir (Wien)*. 1986; 81(3-4):132-134.

25. Day BW, Stringer BW, Wilson J, et al. Glioma surgical aspirate: a viable source of tumor tissue for experimental research. *Cancers (Basel)*. 2013; 5(2):357-371.

26. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. *N Engl J Med*. 2005; 352(10):997-1003.

27. Della Puppa A, Persano L, Masi G, et al. MGMT expression and promoter methylation status may depend on the site of surgical sample collection within glioblastoma: a possible pitfall in stratification of patients? *J Neurooncol*. 2012; 106(1):33-41.

28. Wenger A, Ferreyra Vega S, Kling T, Bontell TO, Jakola AS, Caren H. Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification. *Neuro Onkol*. 2019; 21(5):616-627.

29. Beckner ME, Jane EP, Jankowitz B, et al. Tumor cells from ultrasonic aspirations of glioblastomas migrate and form spheres with radial outgrowth. *Cancer Lett*. 2007; 255(1):135-144.

30. Behnan J, Stangeland B, Langella T, Finocchiaro G, Murrell W, Brinchmann JE. Ultrasonic Surgical Aspirate is a Reliable Source For Culturing Glioblastoma Stem Cells. *Sci Rep*. 2016; 6:32788.
**Figure legends**

**Figure 1 Collection and staining of large *ex vivo* ultrasonic tissue fragments (UTFs)**

A – F, data from participant A only. A) T2-weighted MRI of low-grade glioma in left insula. B) Surgical aspiration of UTFs. C) Trap for UTF collection *in situ*. D) Brightfield image, H&E stained sections of UTFs. E) Sections from one UTF in panel D stained for H&E, Ki-67, IDH1 (R132H) mutation and NeuN. F) Higher magnification images of H&E (top) and IDH1 (R132H) mutation (bottom) sections shown in panel E.

**Figure 2 Surgical biopsy compared with *ex vivo* tumor-core ultrasonic tissue fragments from the same gliomas**

A) Glioma histopathology features found in surgical biopsies compared with tumor-core UTFs. B) Comparison of the results from the surgical biopsy and tumor-core UTFs for percentage of cells expressing nuclear Ki-67 staining and for percentage methylation of MGMT gene promoter (MGMTp) levels analysed from individual gliomas. C) Mean absolute percentage difference in Ki-67 and MGMTp methylation between the surgical biopsy and tumor-core UTFs for each participant. Error bars denote standard error of the mean.

**Figure 3 Screening for glioma infiltration in *ex vivo* ultrasonic tissue fragments with PpIX fluorescence**

A – E, data from one participant. A) Contrast enhanced T1-weighted and FLAIR MRI scans showing a contrast enhancing lesion in the anterior right temporal lobe. B) Intraoperative brain surface images (right, brightfield; left, PpIX fluorescence) of tumor edge (top panels) and tumor core (bottom panels). C) H&E (left panels) and Nestin (right panels) staining of sections through UTFs collected from the tumor edge (upper panels) and the tumor core (lower panels) showing marked glioma infiltration in the tumor core UTFs and sparse glioma
infiltration of the tumor-edge UTFs. **D**) Brightfield images (left panels) and PpIX fluorescence images (right panels) of *ex vivo* UTFs from tumor edge (top panels) and tumor core (bottom panels). **E**) Relative PpIX fluorescence from the tumor edge (n = 3 UTFs, mean 1.6 RFU) and tumor core (n = 3 UTFs, mean 8.5 RFU; p = 0.062, paired t-test) of one glioma. **F**) Mean relative PpIX fluorescence from UTFs collected from the tumor edge (n = 5 gliomas) and tumor core (n = 4 gliomas) (p = 0.01, t-test).

**Figure 4 Heterogeneity of cell proliferation and MGMTp methylation of gliomas**

**A**) Immunocytochemically-labelled glioma cells identified using a circularity filter. Top panel, image (x20) of nestin stained section. Lower panel, Cell bodies of nestin-positive cells labelled in black after analysis. **B**) Density of tumor infiltration in UTFs from the edge and core of gliomas that were either nestin positive or IDH1 (R132H) mutation positive (n = 4 gliomas; p = 0.04, paired t-test). **C**) Relationship between mean PpIX relative fluorescence and mean tumor infiltration of UTFs collected from tumor core and edge (n = 4 gliomas, $r^2 = 0.28$, p = 0.18). **D**) Clustering of cells exhibiting PpIX fluorescence in *ex vivo* UTFs from the tumor edge and core. **E**) Variation in Ki-67 positive cells in different UTFs from one participant. **F**) Plot showing power relationship between density of Ki-67 positive cells and tumor infiltration. Data from UTFs collected from four gliomas (slope for glioma: A = 1.2, $r^2 = 0.96$, p < 0.001; C = 1.4, $r^2 = 0.79$, p = 0.018; F = 1.4, $r^2 = 0.34$, p = 0.17; G = 0.72, $r^2 = 0.90$, p = 0.06). **G**) Variation in methylation status of the MGMT gene promoter from the four gliomas in L. UTFs from tumor edge and core are compared with the surgical biopsy.
Table 1 Neuropathological comparison of ultrasonic tissue fragments and surgical biopsy

|       | Neuropathology - WHO features |       |
|-------|------------------------------|-------|
|       | Ultrasonic tissue fragments (UTFs) | Biopsy |
| A     | • No microvascular proliferation  | • Perineuronal satelitosis |
|       | • No mitotic figures             | • No endothelial hyperplasia |
|       | • No necrosis                    | • No necrosis                |
| B     | • Mitotic activity               | • High mitotic activity      |
|       | • Microvascular proliferation    | • Microvascular proliferation |
|       | • No necrosis                    | • Apoptotic bodies           |
|       |                                 | • Pseudo-palisading necrosis |
| C     | • Mitotic activity               | • Mitotic activity           |
|       | • Microvascular proliferation    | • Microvascular proliferation |
|       | • Necrosis                       | • Necrosis                   |
| D     | • Pleomorphic spindles           | • Pleomorphic spindles       |
|       | • No mitotic activity            | • Mitotic activity           |
|       | • No microvascular proliferation | • Microvascular proliferation |
| E     | • Gemistocytic cells             | • Gemistocytic cells         |
|       | • No mitotic activity            | • Occasional Mitotic activity |
|       | • No microvascular proliferation | • No microvascular proliferation |
|       | • No necrosis                    | • No necrosis                |
| F     | • Necrosis                       | • Necrosis                   |
|       | • Pleomorphic cells              | • Pleomorphic cells           |
|       | • No microvascular proliferation | • Microvascular proliferation |
|       | • No mitotic activity            | • No mitotic activity        |
| G     | • No necrosis                    | • No necrosis                |
|       | • Pleomorphic cells              | • Pleomorphic cells           |
|       | • No microvascular proliferation | • Perinuclear halo formation |
|       | • No mitotic activity            | • mitotic activity           |
Table 2 Clinical information

|   | Age (yrs) | Sex | Classification                              | Location          | Intraoperative PpIX fluorescence |
|---|-----------|-----|---------------------------------------------|-------------------|----------------------------------|
| A | 27        | F   | Oligodendroglioma, IDH1-mutant, grade II    | Left Frontal/Insula| Negative                         |
| B | 62        | M   | Glioblastoma, IDH wildtype, grade IV        | Right Temporal    | Positive                         |
| C | 72        | M   | Glioblastoma, IDH wildtype, grade IV        | Left Parietal     | Positive                         |
| D | 29        | F   | Astrocytoma, IDH1-mutant, grade III         | Left Parietal     | Positive                         |
| E | 71        | F   | Astrocytoma, IDH1-mutant, grade III         | Right Temporal    | Negative                         |
| F | 64        | M   | Glioblastoma, IDH wildtype, grade IV        | Right Temporal    | Positive                         |
| G | 71        | M   | Oligodendroglioma, IDH1-mutant, grade III  | Right Frontal     | Negative                         |
Figure 1
Figure 2
Figure 3
Figure 4

A

B

C

D

E

F

G

NOA-D-19-00100R1 27